tbuckley/cabot-search huggingface dataset:
High-Throughput VDJ Sequencing Is Superior to Quantitative PCR and Flow Cytometry for the Quantification of Minimal Residual Disease In Chronic Lymphocytic Leukemia After Hematopoietic Cell Transplantation.
Authors: Aaron C. Logan, Chunlin Wang, Bita Sahaf, Carol D. Jones, Eleanor L. Marshall, Ismael Buno, Andrew Z. Fire, Michael Mindrinos, James L. Zehnder, Scott D. Boyd, David B. Miklos
Journal: Blood (2010)
Gene Expression Profiling Reveals a Crucial Role for C/EBPbeta in Proliferation Pathways of ALK+ ALCL Cell Lines
Authors: Irina Bonzheim, Martin Irmler, Natasa Anastasov, Margit Klier, Johannes Beckers, Stefania Pittaluga, Falko Fend, Mark Raffeld, Leticia Quintanilla-Martinez
Journal: Blood (2008)
Epithelial Cells of Donor Origin after Allogeneic HCT: Result of Cell Fusion, Transdifferentiation (plasticity) or Transfer of Epithelial Cell Precursors with the Graft?
Authors: Faisal Khan, Sarah Sy, Polly Louie, Megan Smith, Judy Chernos, Robyn Lee, Noureddine Berka, Gary D. Sinclair, Richard Leigh, David Proud, James A. Russell, Jan Storek
Journal: Blood (2008)
Successful treatment of life-threatening ventricular tachycardia with high-dose propranolol under extracorporeal life support and intraaortic balloon pumping.
Authors: Mitsuro Kurose, Kazufumi Okamoto, Toshihide Sato, Riichiro Yatsuda, Kenichi Ogata, Masanobu Yasumoto, Hidenori Terasaki, Hiraaki Goto, Ken Okumura
Journal: Circulation (1993)

The use of propranolol is generally contraindicated in patients with congestive heart failure. However, we successfully used a continuous high-dose infusion of propranolol, in combination with the use of extracorporeal life support (ECLS) and intra-aortic balloon pumping (IABP), to treat refractory life-threatening ventricular tachycardia in a patient with postoperative congestive heart failure. The early combined use of ECLS and IABP before irreversible myocardial damage contributed to the successful outcome.
Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease
Authors: Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Vassilis Koutoulidis, Stavroula Giannouli, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Despoina Fotiou, Dimitrios Ziogas, Ioannis Panagiotidis, Despoina Kalapanida, Eirini Katodritou, Kostas Konstantopoulos, Lia A. Moulopoulos, Meletios A. Dimopoulos
Journal: Blood (2015)
Momelotinib Treatment-Associated Neuropathy: Prevalence, Risk Factors and Outcome in 100 Patients with Myelofibrosis
Authors: Ramy A. Abdelrahman, Kebede Begna, Aref Al-Kali, William J. Hogan, Mark Litzow, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2014)
Does functionalism really deal with the phenomenal side of experience?
Authors: Riccardo Manzotti, Giulio Sandini
Journal: Behavioral and Brain Sciences (2001)

Sensory motor contingencies belong to a functionalistic framework. Functionalism does not explain why and how objective functional relations produce phenomenal experience. O'Regan &amp; Noë (O&amp;N) as well as other functionalists do not propose a new ontology that could support the first person subjective phenomenal side of experience.
Outcome of Invasive Aspergillosis (IA) in 30 Patients with Hematological Cancer (Hem-Ca): Immunity Is (Almost) Everything.
Authors: Marisa H. Miceli, Monica L. Grazziutti, Gail L. Woods, Jose A. Diaz, Somashekar G. Krishna, Elias N. Kiwan, Nayyar Syed, Bart Barlogie, Elias J. Anaissie
Journal: Blood (2006)
Proteomic Analysis of Multiple Myeloma Identifies Upregulation of CRIK Protein, a Novel Protein Regulating Migration and Adhesion
Authors: Hai T. Ngo, Evdoxia Hatjiharissi, Alexey A. Leontovich, Wee Chng, Mena Farag, Xavier Leleu, Xiaoying Jia, Judith Runnels, Aldo Roccaro, Abdel Kareem Azab, Feda Azab, Antonio Sacco, Nicholas Burwick, Molly R. Melhem, Kenneth C. Anderson, Rafael Fonseca, Thomas E. Witzig, Irene M. Ghobrial
Journal: Blood (2008)
New Molecular Strategies for Detection and Quantitation of Clonal Cytotoxic T Cell Responses in Myelodysplasia and Aplastic Anemia.
Authors: Marcin W. Wlodarski, Lukasz Gondek, Zachary Nearman, Yadira Narvaez, Anjali Advani, Alan Lichtin, Matt Kalaycio, Jaroslaw P. Maciejewski
Journal: Blood (2005)
iRegNet3D: three-dimensional integrated regulatory network for the genomic analysis of coding and non-coding disease mutations
Authors: Siqi Liang, Nathaniel D. Tippens, Yaoda Zhou, Matthew Mort, Peter D. Stenson, David N. Cooper, Haiyuan Yu
Journal: Genome biology (2017)

The mechanistic details of most disease-causing mutations remain poorly explored within the context of regulatory networks. We present a high-resolution three-dimensional integrated regulatory network (iRegNet3D) in the form of a web tool, where we resolve the interfaces of all known transcription factor (TF)-TF, TF-DNA and chromatin-chromatin interactions for the analysis of both coding and non-coding disease-associated mutations to obtain mechanistic insights into their functional impact. Using iRegNet3D, we find that disease-associated mutations may perturb the regulatory network through diverse mechanisms including chromatin looping. iRegNet3D promises to be an indispensable tool in large-scale sequencing and disease association studies.
Predictive Factors for Poor Outcome in Danaparoid-Treated HIT-Patients: A French Multicentre Case-Control Study.
Authors: IsmaïL. Elalamy, B. Tardy-Poncet, A. Mulot, E. DeMaistre, Claire Pouplard, Philippe Nguyen, M. Trossaert, Y. Blanloeil, B. Cleret, Yves Gruel, T. Lecompte, B. Tardy
Journal: Blood (2008)
Zinc Finger Nuclease (ZFN) Targeted Homologous Recombination Assay Detects Elevated Inter Homologous Recombination Activity and Copy Neutral Loss of Heterozygosity (CN-LOH) in Internal Tandem Duplication Mutated FLT3 (FLT3-ITD) Acute Myeloid Leukaemia (AML)
Authors: Terry J Gaymes, Ghulam J Mufti
Journal: Blood (2015)
The Metabolic SYNDROME and the RISK of Venous Thrombosis: RESULTS of AN Individual LEVEL Patient Meta-ANALYSIS
Authors: Francesco Dentali, Cihan Ay, Moon Jang, Matteo di Minno, Ingrid Pabinger, Doyeun Oh, Giovanni di Minno, Alessandro Squizzato, Anna Maria Grandi, Walter Ageno
Journal: Blood (2010)
A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
Authors: Simona Piemontese, F. Ciceri, M. Labopin, W. Arcese, S. Kyrcz-Krzemien, S. Santarone, H. Huang, D. Beelen, N. C. Gorin, C. Craddock, Z. Gulbas, A. Bacigalupo, M. Mohty, A. Nagler
Journal: Journal of Hematology & Oncology (2017)

In the absence of a HLA-matched related or matched unrelated donor, allogeneic stem cell transplantation (allo-SCT) from mismatched unrelated donors or haploidentical donors are potential alternatives for patients with acute leukemia with an indication to allo-SCT. The objective of this study was to compare the outcome of allo-SCT from T cell-replete haploidentical (Haplo) versus matched (MUD 10/10) or mismatched unrelated donor at a single HLA-locus (MMUD 9/10) for patients with acute leukemia in remission. Two hundred sixty-five adult patients with de novo acute leukemia in first or second remission that received a Haplo-SCT between January 2007 and December 2013 were compared with 2490 patients receiving a MUD 10/10 and 813 receiving a MMUD 9/10. Propensity score weighted analysis was conducted in order to control for disease risk imbalances between the groups. The weighted 3-year non-relapse mortality and relapse incidence were 29 and 30% for Haplo, 21 and 29% for MUD 10/10, and 29 and 25% for MMUD 9/10, respectively. The weighted 3-year leukemia-free survival (LFS) and overall survival (OS) were 41 and 46% for Haplo, 50 and 56% for MUD 10/10, and 46 and 48% for MMUD 9/10, respectively. Using weighted Cox model, both LFS and OS were significantly higher in transplants from MUD 10/10 compared from those in Haplo but not different between transplants from MMUD 9/10 and Haplo. The type of donor was not significantly associated with neither acute nor chronic graft-versus-host disease. Patients with acute leukemia in remission have better outcomes if transplanted from a MUD 10/10. We did not find any significant difference in outcome between transplants from MMUD 9/10 and Haplo, suggesting that both can be equally used in the absence of a 10/10 MUD. KEY POINT 1: Better outcomes using fully (10/10) matched unrelated donor for allo-SCT in acute leukemia in remission. KEY POINT 2: Similar outcomes after allo-SCT from unmanipulated haploidentical graft or mismatched (9/10) unrelated donor in acute leukemia in remission.
Abstract 15697: Dyrk2 Coordinates Repressor Function of GSK-3{beta} on Protein Synthesis in Cardiac Myocytes
Authors: Celine S Weiss, Marco M Ochs, Marco Hagenmuller, Sebastian J Buss, David Wolf, Junichi Sadoshima, Hugo A Katus, Stefan E Hardt
Journal: Circulation (2010)

Introduction: A prerequisite of hypertrophic response of the myocardium is an increase in protein synthesis. A central regulator of translation initiation is eIF2B, the Guanine Nucleotide Exchange ...
Review of the Development of Methods for Characterization of Microspheres for Use in Embolotherapy: Translating Bench to Cathlab
Authors: Marcus Caine, Dario Carugo, Xunli Zhang, Martyn Hill, Matthew R. Dreher, Andrew L. Lewis
Journal: Advanced Healthcare Materials (2017)

Therapeutic embolotherapy is the deliberate occlusion of a blood vessel within the body, which can be for the prevention of internal bleeding, stemming of flow through an arteriovenous malformation, or occlusion of blood vessels feeding a tumor. This is achieved using a wide selection of embolic devices such as balloons, coils, gels, glues, and particles. Particulate embolization is often favored for blocking smaller vessels, particularly within hypervascularized tumors, as they are available in calibrated sizes and can be delivered distally via microcatheters for precise occlusion with associated locoregional drug delivery. Embolic performance has been traditionally evaluated using animal models, but with increasing interest in the 3R's (replacement, reduction, refinement), manufacturers, regulators, and clinicians have shown interest in the development of more sophisticated in vitro methods for evaluation and prediction of in vivo performance. Herein the current progress in developing bespoke techniques incorporating physical handling, fluid dynamics, occlusive behavior, and sustained drug elution kinetics within vascular systems is reviewed. While it is necessary to continue to validate the safety of such devices in vivo, great strides have been made in the development of bench tests that better predict the behavior of these products aligned with the principles of the 3R's.
Profound loss of esophageal tissue differentiation in patients with eosinophilic esophagitis
Authors: Mark Rochman, Jared Travers, Cora E. Miracle, Mary C. Bedard, Ting Wen, Nurit P. Azouz, Julie M. Caldwell, Kiran KC, Joseph D. Sherrill, Benjamin P. Davis, Jeffrey K. Rymer, Kenneth M. Kaufman, Bruce J. Aronow, Marc E. Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2017)
Manageable and Transient Hematologic Toxicity Associated with 90Y-Ibritumomab Tiuxetan (90Y-Zevalin) Consolidation of FCM Chemotherapy in Mantle Cell Lymphoma (MCL) Patients.
Authors: W. Jurczak, M. Szostek, A. Giza, Z. Rudzki, A. Skotnicki
Journal: Blood (2005)
Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.
Authors: Pieter Sonneveld, Wim van Putten, Douwe Biesma, Harald Holte, Marinus van Marwijk Kooij, Mark Henri H. Kramer, P.W. Wijermans, Monique Steijaert, Gustaaf W. van Imhoff, P.J. Lugtenburg, P.C. Huijgens, Mikael Eriksson
Journal: Blood (2006)
Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.
Authors: Charles L. Sawyers, H. Kantarjian, N. Shah, J. Cortes, R. Paquette, N. Donato, J. Nicoll, E. Bleickardt, T.-T. Chen, M. Talpaz
Journal: Blood (2005)
Abstract P163: Are Coronary Artery Disease and Type 2 Diabetes Causally Related to Age of Menopause?
Authors: N. Charlotte Onland-Moret, Claire Lovern, Marlies Voorhuis, Ching-Ti Liu, Frank J Broekmans, Nick J Wareham, Joanne M Murabito, Yvonne T van der Schouw
Journal: Circulation (2016)

Background: Women who enter the menopause at a younger age, are at an increased risk of cardiovascular disease (CVD) and type 2 diabetes (T2D) in later life. However, we have previously reported that development of an unfavourable cardiovascular risk profile premenopausally accelerates the onset of menopause. Furthermore, we reported that women who were diagnosed with diabetes at a very young age also reached menopause earlier. Hence, the direction of the relationship between coronary heart disease (CHD), T2D and the onset of menopause is unclear, and whether the associations are causal is also unclear. Hypothesis: In this study we hypothesize that CHD and/or T2D are causally related to the age of menopause, and studied this using genetic risk scores for CHD and T2D. Methods: Single nucleotide polymorphisms which had previously reached genome-wide significance for CHD and T2D were, individually and as a genetic risk score, tested for an association with age at natural menopause in over 50,000 women from three large consortia: the ITMAT/Broad/CARe (IBC) consortium, the ReproGen consortium, and the EPIC-InterAct consortium. From these consortia all women with a known age at natural menopause between 40 and 60 years were included. We used the genotyping array of the IBC consortium for the selection of the SNPs. The IBC array is a gene-centric genotyping array developed for replication and fine mapping and incorporates about 50K SNPs that capture information on 2000 genetic regions related to cardiovascular, inflammatory, and metabolic regions. The selected SNPs were also requested for analyses in the other two consortia. A total of 18 single nucleotide polymorphisms for CHD and 28 for T2D were selected. In the EPIC-InterAct study we used these SNPs to calculate unweighted individual level genetic risk scores. Results: No statistically significant associations were found for any of the CHD SNPs, nor for the T2D SNPs, nor for the genetic risk scores. Conclusions: Previous findings that women with an increased risk of CHD or T2D also have an increased risk of entering the menopause at younger ages, could not be supported by our data. Furthermore, the association between cardiometabolic disease and earlier timing of menopause does not seem to be causal. However, this finding does not exclude the possibility that the reverse association can be causal.
Pilot Trial of Rituximab for the Prevention of Epstein Barr Virus B Cell Lymphoproliferative Disorder (EBV-LPD) Following T Cell Depleted (TCD) Unrelated or HLA-Mismatched Related Hematopoietic Stem Cell Transplantation.
Authors: Trudy N. Small, Nancy A. Kernan, Ann Jakubowski, James W. Young, Susan Prockop, Miguel-Angel Perales, Richard J. O’Reilly, Esperanza B. Papadopoulos
Journal: Blood (2006)
The ties that bind
Authors: Andreas Lundh, Lisa Bero
Journal: BMJ (2017)

Authors’ financial ties may be a source of bias in trials and must be disclosed in full

Substantial evidence shows that sponsorship or funding of trials of drugs and devices by companies producing the drug or device results in publications that tend to favour the sponsor’s product.1 Personal financial ties—including travel expenses, honorariums, payment for advisory work, or stock ownership—between commercial companies and authors of reviews, meta-analyses, editorials, and letters are also associated with conclusions favourable to the sponsor.23

However, studies of the relation between trial authors’ financial ties and trial results have been conflicting.4 One reason for the inconsistent results is that trials by authors with financial ties are also often funded by industry, which may confound the association of financial ties with favourable outcomes.

Ahn and colleagues (doi:10.1136/bmj.i6770) investigated the association between financial ties of principal investigators and outcomes in a random sample of 195 drug trials published in 2013.4 They found that trials authored by principal investigators with financial ties to drug manufacturers were more likely than other trials to …
Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
Authors: Yucai Wang, Nicolaus Wagner-Bartak, Shouhao Zhou, Nathan Fowler, Maria Lourdes Dela Rosa, Donglu Zhao, Jorge E. Romaguera, Sattva S. Neelapu, Fredrick B. Hagemeister, Michelle A. Fanale, Yasuhiro Oki, Jatin J. Shah, Sheeba K. Thomoas, Chitra M. Hosing, Liang Zhang, Maria Badillo, Wendy Chen, Qingqing Cai, Dehui Zou, Richard E. Champlin, Luis E. Fayad, Hun Ju Lee, Michael Wang
Journal: Blood (2015)
High Dose Intensive Chemotherapy, as Is Standard in Childhood Leukemia, Is Feasible and Efficacious in Adult Patients with Acute Lymphoblastic Leukemia (ALL) up to the Age of 40: Results From the Dutch-Belgian HOVON-70 Study.
Authors: A. W Rijneveld, B. van der Holt, S. M. G. J. Daenen, B. J. Biemond, A. A van de Loosdrecht, O. de Weerdt, P. Muus, J. Maertens, V. Mattijssen, H. Demuynck, Mcjc Legdeur, P.W. Wijermans, S. Wittebol, F. Spoelstra, A. W. Dekker, G.J. Ossenkoppele, J. J. Cornelissen, R. Willemze
Journal: Blood (2009)
Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines
Authors: Lavinia Biamonte, Cinzia Federico, Eugenio Morelli, Emanuela Leone, Maria Eugenia Gallo Cantafio, Maria Teresa Di Martino, Nicola Amodio, Marco Rossi, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood (2015)
Abstract 17868: Longitudinal Trajectories of Clinical Risk Factors Are Associated With Incident Cardiovascular Disease in the Community
Authors: Matthew Nayor, Asya Lyass, Michael J Pencina, Ramachandran S Vasan, Connie W Tsao
Journal: Circulation (2016)

Introduction: Cardiovascular disease (CVD) risk prediction is traditionally based on values from a single time point. The relative associations of longitudinal trajectories of clinical risk factors...
Predicting academic performance of medical students: the first three years
Authors: C Höschl, J Kozený
Journal: American Journal of Psychiatry (1997)

The purpose of this exploratory study was to identify a cluster of variables that would most economically explain variations in the grade point averages of medical students during the first 3 years of study.Data were derived from a study of 92 students admitted to the 3rd Faculty of Medicine in 1992-1993 academic year and who were still in the medical school at the end of the sixth semester (third year). Stepwise regression analysis was used to build models for predicting log-transformed changes in grade point average after six semesters of study-at the end of the first, second, and third years. Predictor variables were chosen from four domains: 1) high school grade point averages in physics, mathematics, and the Czech language over 4 years of study, 2) results of admission tests in biology, chemistry, and physics, 3) admission committee's assessment of the applicant's ability to reproduce a text, motivation to study medicine, and social maturity, and 4) scores on the sentimentality and attachment scales of the Tridimensional Personality Questionnaire.The regression model, which included performance in high school physics, results of the admission test in physics, assessment of the applicant's motivation to study medicine, and attachment scale score, accounted for 32% of the change in grade point average over six semesters of study. The regression models using the first-, second-, and third-year grade point averages as the dependent variables showed slightly decreasing amounts of explained variance toward the end of the third year of study and within domains, changing the structure of predictor variables.The results suggest that variables chosen from the assessment domains of high school performance, written entrance examination, admission interview, and personality traits may be significant predictors of academic success during the first 3 years of medical study.
MiR-155 Amplifies AKT and NFkB Signaling By Targeting Multiple Regulators of BCR Signal in DLBCL
Authors: Ewa Jablonska, Patryk Gorniak, Weronika Prusisz, Przemyslaw Kiliszek, Maciej Szydlowski, Tomasz Sewastianik, Emilia Bialopiotrowicz, Anna Polak, Monika Prochorec-Sobieszek, Anna Szumera-Cieckiewicz, Krzysztof Warzocha, Przemyslaw Juszczynski
Journal: Blood (2015)
Sensitized signalling between L-type Ca<sup>2+</sup>channels and ryanodine receptors in the absence or inhibition of FKBP12.6 in cardiomyocytes
Authors: Yan-Ting Zhao, Yun-Bo Guo, Lei Gu, Xue-Xin Fan, Hua-Qian Yang, Zheng Chen, Peng Zhou, Qi Yuan, Guang-Ju Ji, Shi-Qiang Wang
Journal: Cardiovascular Research (2016)

The heart contraction is controlled by the Ca2+-induced Ca2+ release (CICR) between L-type Ca2+ channels and ryanodine receptors (RyRs). The FK506-binding protein FKBP12.6 binds to RyR subunits, but its role in stabilizing RyR function has been debated for long. Recent reports of high-resolution RyR structure show that the HD2 domain that binds to the SPRY2 domain of neighbouring subunit in FKBP-bound RyR1 is detached and invisible in FKBP-null RyR2. The present study was to test the consequence of FKBP12.6 absence on the in situ activation of RyR2.Using whole-cell patch-clamp combined with confocal imaging, we applied a near threshold depolarization to activate a very small fraction of LCCs, which in turn activated RyR Ca2+ sparks stochastically. FKBP12.6-knockout and FK506/rapamycin treatments increased spark frequency and LCC-RyR coupling fidelity without altering LCC open probability. Neither FK506 nor rapamycin further altered LCC-RyR coupling fidelity in FKBP12.6-knockout cells. In loose-seal patch-clamp experiments, the LCC-RyR signalling kinetics, indexed by the delay for a LCC sparklet to trigger a RyR spark, was accelerated after FKBP12.6 knockout and FK506/rapamycin treatments. These results demonstrated that RyRs became more sensitive to Ca2+ triggers without FKBP12.6. Isoproterenol (1 μM) further accelerated the LCC-RyR signalling in FKBP12.6-knockout cells. The synergistic sensitization of RyRs by catecholaminergic signalling and FKBP12.6 dysfunction destabilized the CICR system, leading to chaotic Ca2+ waves and ventricular arrhythmias.FKBP12.6 keeps the RyRs from over-sensitization, stabilizes the potentially regenerative CICR system, and thus may suppress the life-threatening arrhythmogenesis.